Noninvasive treatment for invasive squamous cell carcinoma of the head and neck

Nonmelanoma skin cancer represents the most common malignancy in the United States, and the incidence is increasing. In the United States alone, average annual treatment costs are in the billions. Although basal cell carcinoma (BCC) is considered the most common skin cancer, recent studies suggest the incidence of squamous cell carcinoma (SCC) has increased creating a SCC:BCC ratio of 1.0. Many treatment modalities are used for SCC including Mohs micrographic surgery, but there are currently no FDA-approved topical therapies for SCCs.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research